EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia

Daniela-Carmen Ababei iD, Veronica Bild iD, Ioana Macadan iD, Alexandru Vasincu iD, Răzvan-Nicolae Rusu iD, Mihaela Blaj, Gabriela Dumitrița Stanciu iD, Radu-Marian Lefter, Walther Bild iD

Pharmaceutics · 06.09.2023 · 15 (9) · 2290

DOI: 10.3390/pharmaceutics15092290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 06.09.2023. Verfasst von Daniela-Carmen Ababei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacodynamics and Clinical Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Ro…. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: project"Net4SCIENCE: Applied doctoral and postdoctoral research network in the fields of smart specialization Health and Bioeconomy", Net4SCIENCE: Applied doctoral and postdoctoral research network in the fields of smart specialization Health and Bioeconomy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Renin–Angiotensin System (RAS) has attracted considerable interest beyond its traditional cardiovascular role due to emerging data indicating its potential involvement in neurodegenerative diseases, including Alzheimer’s dementia (AD). This review investigates the therapeutic implications of RAS modulators, specifically focusing on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and renin inhibitors in AD. ACEIs, commonly used for hypertension, show promise in AD by reducing angiotensin (Ang) II levels. This reduction is significant as Ang II contributes to neuroinflammation, oxidative stress, and β-amyloid (Aβ) accumulation, all implicated in AD pathogenesis. ARBs, known for vasodilation, exhibit neuroprotection by blocking Ang II receptors, improving cerebral blood flow and cognitive decline in AD models. Renin inhibitors offer a novel approach by targeting the initial RAS step, displaying anti-inflammatory and antioxidant effects that mitigate AD degeneration. Preclinical studies demonstrate RAS regulation’s favorable impact on neuroinflammation, neuronal damage, cognitive function, and Aβ metabolism. Clinical trials on RAS modulators in AD are limited, but with promising results, ARBs being more effective that ACEIs in reducing cognitive decline. The varied roles of ACEIs, ARBs, and renin inhibitors in RAS modulation present a promising avenue for AD therapeutic intervention, requiring further research to potentially transform AD treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

ACE inhibitorsARBsAlzheimer dementiaaliskirenangiotensin IIrenin–angiotensin

Autor:innen und Institutionen

  • Department of Pharmacodynamics and Clinical Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
  • Center of Biomedical Research, Romanian Academy, Iasi Branch, 8 Carol I Avenue, 700506 Iasi, Romania.
  • Department of Anaesthesiology and Intensive Therapy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
  • Center for Advanced Research and Development in Experimental Medicine (CEMEX), "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
  • Department of Physiology, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.

ORCID-Profile: Daniela-Carmen Ababei, Veronica Bild, Ioana Macadan, Alexandru Vasincu, Răzvan-Nicolae Rusu, Gabriela Dumitrița Stanciu, Walther Bild

Förderung

  • project"Net4SCIENCE: Applied doctoral and postdoctoral research network in the fields of smart specialization Health and Bioeconomy"
  • Net4SCIENCE: Applied doctoral and postdoctoral research network in the fields of smart specialization Health and Bioeconomy

Zitieren

APA

Ababei, D. C., Bild, V., Macadan, I., Vasincu, A., Rusu, R. N., Blaj, M., Stanciu, G. D., Lefter, R. M., & Bild, W. (2023). Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia. Pharmaceutics, 15(9), 2290. https://doi.org/10.3390/pharmaceutics15092290

Vancouver

Ababei DC, Bild V, Macadan I, Vasincu A, Rusu RN, Blaj M, et al. Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia. Pharmaceutics. 2023;15(9):2290. doi:10.3390/pharmaceutics15092290

BibTeX
@article{Ababei2023,
  author = {Ababei, Daniela-Carmen and Bild, Veronica and Macadan, Ioana and Vasincu, Alexandru and Rusu, Răzvan-Nicolae and Blaj, Mihaela and Stanciu, Gabriela Dumitrița and Lefter, Radu-Marian and Bild, Walther},
  title = {Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {9},
  pages = {2290},
  doi = {10.3390/pharmaceutics15092290}
}
Kostenlos starten →